Speedy NICE Support For Eisai's Lenvima In Liver Cancer
It took NICE nearly three years to offer routine access to Lenvima for thyroid cancer but it has taken just three months from European approval to recommend the drug for advanced or unresectable hepatocellular carcinoma.
You may also be interested in...
The drug maker looks set to join fellow Japanese firms Sony and Panasonic in moving its European legal base out of the UK as the uncertainties surrounding Brexit show little sign of being resolved.
Japan's Eisai is considering all options including legal action and reducing its investment in the UK to force NICE to make its potential blockbuster TKI cancer drug lenvatinib available sooner to patients with advanced thyroid cancer via the publicly-funded National Health Service.
With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.